{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-043730","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.556673+00:00","generated_at":"2026-05-21T04:54:12.548935+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adial Pharma Q1 net loss $2.2M; warrants raise $2.75M; AD04 Phase 2 meeting set for July","bullets":["Cash $2.4M at March 31; with $2.75M warrant proceeds, runway into Q4 2025.","Net loss $2.2M vs $6.5M YoY; reduction due to $4.5M 2024 inducement expense not recurring.","Entered warrant inducement: exercised 3.7M shares at $0.74, gross proceeds ~$2.75M.","Received six-figure milestone from Adovate for asthma candidate Phase 1; eligible for up to $83M in milestones plus royalties.","FDA supports 505(b)(2) bridging strategy; End of Phase 2 meeting planned for July 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-043730","json":"https://secwatch.observer/filing/0001213900-25-043730.json","markdown":"https://secwatch.observer/filing/0001213900-25-043730.md","text":"https://secwatch.observer/filing/0001213900-25-043730.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025043730/0001213900-25-043730-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025043730/ea0242253-8k_adial.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:54:12.548935+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}